TrAMPoline Pharma

Executive Summary

TrAMPoline Pharma is a preclinical-stage cellular immunotherapy company developing personalized tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. Its lead candidate, MightyTIL, is a gene-engineered TIL therapy designed to enhance antitumor activity compared to conventional unmodified TILs. The company is initially targeting orphan indications such as sarcoma and head and neck cancer, as well as melanoma, where TIL therapy has established proof of concept. Preclinical data in multiple animal models show significantly improved tumor regression, supporting the rationale for clinical translation. The company is currently advancing toward Phase 1 clinical trials, leveraging its proprietary gene engineering platform to address key limitations of TIL therapy, including persistence and potency in the immunosuppressive tumor microenvironment. While the field of cell therapy for solid tumors is challenging, TrAMPoline's differentiated approach and focus on orphan indications position it for potential accelerated development pathways.

Upcoming Catalysts (preview)

• Q4 2026FDA Orphan Drug Designation for MightyTIL in sarcoma or head and neck cancer75% success
• H1 2027First patient dosed in Phase 1 trial of MightyTIL60% success
• Q2 2026Presentation of updated preclinical data at a major medical conference90% success